<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">32491527</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK557595</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-60330">Rufinamide</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Humayun</LastName><ForeName>Mohammad Junaid</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadhwa</LastName><ForeName>Roopma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>South Carolina Department of Mental Health</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Rufinamide is one of the anti-seizure drugs (ASD) used as an add-on therapy to treat seizures associated with Lennox Gastaut syndrome, and it is structurally unrelated to other traditional ASDs. This CME activity provides a brief and illustrative review of this drug's FDA-approved indications and pharmacodynamic and pharmacokinetic properties. This activity will also highlight the side effects, contraindications, and dosing regimens of this drug and will also shed light on the practice parameters of the American Academy of Neurology guidelines regarding the utility of this drug in clinical practice.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s2">Indications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s3">Mechanism of Action</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s4">Administration</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s5">Adverse Effects</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s6">Contraindications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s7">Monitoring</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s8">Toxicity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s9">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s10">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s11">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>4</Month><Day>25</Day></ContributionDate><ReferenceList><Reference><Citation>Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008 Jul;49(7):1123-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18503564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr. 2010 Jan;10(1):1-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812713</ArticleId><ArticleId IdType="pubmed">20126329</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks ED, Scott LJ. Rufinamide. CNS Drugs. 2006;20(9):751-60; discussion 761.</Citation><ArticleIdList><ArticleId IdType="pubmed">16953653</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018 Mar;39(3):403-414.</Citation><ArticleIdList><ArticleId IdType="pubmed">29124439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimpf R, Veltmann C, Papavassiliu T, Rudic B, Göksu T, Kuschyk J, Wolpert C, Antzelevitch C, Ebner A, Borggrefe M, Brandt C. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012 May;9(5):776-81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482382</ArticleId><ArticleId IdType="pubmed">22245794</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol. 2010 Jan;159(1):58-69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823352</ArticleId><ArticleId IdType="pubmed">19563537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Epilepsy Res. 2016 Mar;121:1-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26827266</ArticleId></ArticleIdList></Reference><Reference><Citation>Crettenand M, Rossetti AO, Buclin T, Winterfeld U. [Use of antiepileptic drugs during breastfeeding : What do we tell the mother?] Nervenarzt. 2018 Aug;89(8):913-921.</Citation><ArticleIdList><ArticleId IdType="pubmed">29487964</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y, Inoue Y, Usui N, Imai K, Kagawa Y, Takahashi Y. Therapeutic drug monitoring for rufinamide in Japanese patients with epilepsy: Focus on drug interactions, tolerability, and clinical effectiveness. Ther Drug Monit. 2022 Feb 21;</Citation><ArticleIdList><ArticleId IdType="pubmed">35213526</ArticleId></ArticleIdList></Reference><Reference><Citation>Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18401024</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010 Jan;10(1):119-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014 Dec;16(4):409-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">25515681</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D. 2016 Dec;16(4):303-316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114206</ArticleId><ArticleId IdType="pubmed">27766590</ArticleId></ArticleIdList></Reference><Reference><Citation>Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018 Dec 11;91(24):1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">30530563</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, Spalice A, Habetswallner F, Fels A, Verrotti A, D'Aniello A, Mangano S, Balestri A, Curatolo P, Pascotto A. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol. 2011 Feb;18(2):246-251.</Citation><ArticleIdList><ArticleId IdType="pubmed">20666837</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32491527</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">32491527</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK557595</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-60330">Rufinamide</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Humayun</LastName><ForeName>Mohammad Junaid</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadhwa</LastName><ForeName>Roopma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>South Carolina Department of Mental Health</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Rufinamide is one of the anti-seizure drugs (ASD) used as an add-on therapy to treat seizures associated with Lennox Gastaut syndrome, and it is structurally unrelated to other traditional ASDs. This CME activity provides a brief and illustrative review of this drug's FDA-approved indications and pharmacodynamic and pharmacokinetic properties. This activity will also highlight the side effects, contraindications, and dosing regimens of this drug and will also shed light on the practice parameters of the American Academy of Neurology guidelines regarding the utility of this drug in clinical practice.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s2">Indications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s3">Mechanism of Action</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s4">Administration</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s5">Adverse Effects</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s6">Contraindications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s7">Monitoring</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s8">Toxicity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s9">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s10">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-60330" sec="article-60330.s11">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>4</Month><Day>25</Day></ContributionDate><ReferenceList><Reference><Citation>Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008 Jul;49(7):1123-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18503564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr. 2010 Jan;10(1):1-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812713</ArticleId><ArticleId IdType="pubmed">20126329</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks ED, Scott LJ. Rufinamide. CNS Drugs. 2006;20(9):751-60; discussion 761.</Citation><ArticleIdList><ArticleId IdType="pubmed">16953653</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018 Mar;39(3):403-414.</Citation><ArticleIdList><ArticleId IdType="pubmed">29124439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimpf R, Veltmann C, Papavassiliu T, Rudic B, Göksu T, Kuschyk J, Wolpert C, Antzelevitch C, Ebner A, Borggrefe M, Brandt C. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012 May;9(5):776-81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482382</ArticleId><ArticleId IdType="pubmed">22245794</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol. 2010 Jan;159(1):58-69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823352</ArticleId><ArticleId IdType="pubmed">19563537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Epilepsy Res. 2016 Mar;121:1-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26827266</ArticleId></ArticleIdList></Reference><Reference><Citation>Crettenand M, Rossetti AO, Buclin T, Winterfeld U. [Use of antiepileptic drugs during breastfeeding : What do we tell the mother?] Nervenarzt. 2018 Aug;89(8):913-921.</Citation><ArticleIdList><ArticleId IdType="pubmed">29487964</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y, Inoue Y, Usui N, Imai K, Kagawa Y, Takahashi Y. Therapeutic drug monitoring for rufinamide in Japanese patients with epilepsy: Focus on drug interactions, tolerability, and clinical effectiveness. Ther Drug Monit. 2022 Feb 21;</Citation><ArticleIdList><ArticleId IdType="pubmed">35213526</ArticleId></ArticleIdList></Reference><Reference><Citation>Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18401024</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010 Jan;10(1):119-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014 Dec;16(4):409-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">25515681</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D. 2016 Dec;16(4):303-316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114206</ArticleId><ArticleId IdType="pubmed">27766590</ArticleId></ArticleIdList></Reference><Reference><Citation>Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018 Dec 11;91(24):1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">30530563</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, Spalice A, Habetswallner F, Fels A, Verrotti A, D'Aniello A, Mangano S, Balestri A, Curatolo P, Pascotto A. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol. 2011 Feb;18(2):246-251.</Citation><ArticleIdList><ArticleId IdType="pubmed">20666837</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32491527</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
